Overview of the LUX-Lung clinical trial program of afatinib for non-small cell lung cancer

Namita Sharma; Stephen Graziano

doi:10.1016/j.ctrv.2018.06.018

Overview of the LUX-Lung clinical trial program of afatinib for non-small cell lung cancer

Cancer Treat Rev. 2018 Sep:69:143-151. doi: 10.1016/j.ctrv.2018.06.018. Epub 2018 Jun 28.

Authors

Namita Sharma¹, Stephen Graziano²

Affiliations

¹ Hematology/Medical Oncology, GCMC Cancer Center, 1800 Mulberry Street, Scranton, PA 18510, United States. Electronic address: dr.nams@gmail.com.
² SUNY Upstate Medical University, 750 East Adams Street, Syracuse, NY 13210, United States. Electronic address: grazians@upstate.edu.

PMID: 30014952
DOI: 10.1016/j.ctrv.2018.06.018

Abstract

Tyrosine kinase inhibitors (TKIs) have emerged as first-line treatment for the management of epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer (NSCLC). Erlotinib and gefitinib were the initial TKIs to be approved for lung cancer and showed improved response rates compared with chemotherapy. Afatinib is an irreversible ErbB family blocker that has also been shown to be active in EGFR-mutated NSCLC. Afatinib has been tested as first-line treatment of advanced NSCLC in the LUX-Lung trial program, as well as in the second- and third-line settings. In this article, we will review the data from the 8 reported LUX-Lung trials.

Keywords: Afatinib; Epidermal growth factor receptor; ErbB receptors; Non-small cell lung cancer; Tyrosine kinase inhibitor.

Publication types

Review

MeSH terms

Afatinib
Carcinoma, Non-Small-Cell Lung / drug therapy*
Clinical Trials as Topic*
Humans
Lung Neoplasms / drug therapy*
Prognosis
Quinazolines / therapeutic use*
Radiation-Sensitizing Agents / therapeutic use*

Substances

Quinazolines
Radiation-Sensitizing Agents
Afatinib